{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:39:45Z","timestamp":1785886785159,"version":"3.56.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2020,11,14]],"date-time":"2020-11-14T00:00:00Z","timestamp":1605312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>We aimed to compare tuberculosis (TB) risk during biologics treatment between patients with RA who did (prophylaxis) and did not (non-prophylaxis) undergo chemoprophylaxis following pre-biologic latent TB screening in Korea of an intermediate TB burden.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Using the 2002\u201316 Korea National Health Insurance database, we conducted a cohort study examining TB risk, defined by International Classification of Diseases Tenth Revision codes plus anti-TB drugs, among RA patients initiating a biologic drug with and without chemoprophylaxis after screening triage for latent TB. To control baseline confounding, we used propensity score-based fine stratification (PSS) and weighting. Cox proportional hazards models estimated hazard ratios and 95% CIs comparing TB risk between the prophylaxis vs non-prophylaxis groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The PSS-weighted study cohort (mean age 57.0\u2009years; 81.3% female) included 2249 and 7225 RA patients in the prophylaxis and non-prophylaxis groups, respectively. During 2.42\u2009years of biologics treatment, 118 patients developed TB with the incidence rate per 100 person-years of 0.33 in the prophylaxis and 0.63 in the non-prophylaxis groups. The PSS-weighted hazard ratio (95% CI) for TB associated with the prophylaxis was 0.52 (0.32, 0.86). During the follow-up time, the incidence rate of TB remained consistently low in the prophylaxis group but it was highest in the first year, then time-dependently declined in the non-prophylaxis group.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This population-based cohort study warns that the current screening-based preventive strategy generates a substantially higher TB risk after biologics initiation among screening-negative patients compared with screening-positive patients receiving chemoprophylaxis, when the background TB burden is not low.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaa702","type":"journal-article","created":{"date-parts":[[2020,10,17]],"date-time":"2020-10-17T11:10:56Z","timestamp":1602933056000},"page":"2755-2764","source":"Crossref","is-referenced-by-count":7,"title":["Tuberculosis risk with biologics by screening-guided preventive strategy in rheumatoid arthritis under intermediate tuberculosis burden"],"prefix":"10.1093","volume":"60","author":[{"given":"Anna","family":"Shin","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun Jong","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0703-1208","authenticated-orcid":false,"given":"Eun Bong","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1575-9007","authenticated-orcid":false,"given":"Yeong Wook","family":"Song","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2517-3579","authenticated-orcid":false,"given":"Seoyoung C","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Inflammation, and Immunity, Brigham and Women\u2019s Hospital, Boston, MA, USA"},{"name":"Division of Pharmacoepidemiology & Pharmacoeconomics, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9697-1159","authenticated-orcid":false,"given":"Eun Ha","family":"Kang","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,11,14]]},"reference":[{"key":"2021061821290729600_keaa702-B1","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/art.1780370408","article-title":"The mortality of rheumatoid arthritis","volume":"37","author":"Wolfe","year":"1994","journal-title":"Arthritis Rheum"},{"key":"2021061821290729600_keaa702-B2","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1002\/art.10524","article-title":"Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study","volume":"46","author":"Doran","year":"2002","journal-title":"Arthritis Rheum"},{"key":"2021061821290729600_keaa702-B3","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1136\/annrheumdis-2011-201108","article-title":"Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register","volume":"72","author":"Galloway","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2021061821290729600_keaa702-B4","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1136\/annrheumdis-2013-203407","article-title":"Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) study","volume":"73","author":"Baddley","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2021061821290729600_keaa702-B5","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"key":"2021061821290729600_keaa702-B6","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/art.11137","article-title":"Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report","volume":"48","author":"G\u00f3mez-Reino","year":"2003","journal-title":"Arthritis Rheum"},{"key":"2021061821290729600_keaa702-B7","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1002\/art.21137","article-title":"Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden","volume":"52","author":"Askling","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2021061821290729600_keaa702-B8","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1136\/annrheumdis-2016-210708","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis","volume":"76","author":"Ramiro","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2021061821290729600_keaa702-B9","doi-asserted-by":"crossref","first-page":"16076","DOI":"10.1038\/nrdp.2016.76","article-title":"Tuberculosis","volume":"2","author":"Pai","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"2021061821290729600_keaa702-B10","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S1473-3099(03)00545-0","article-title":"Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management","volume":"3","author":"Gardam","year":"2003","journal-title":"Lancet Infect Dis"},{"key":"2021061821290729600_keaa702-B11","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1002\/art.21043","article-title":"Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists","volume":"52","author":"Carmona","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2021061821290729600_keaa702-B12","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.autrev.2015.01.011","article-title":"Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice","volume":"14","author":"Cantini","year":"2015","journal-title":"Autoimmun Rev"},{"key":"2021061821290729600_keaa702-B13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2021061821290729600_keaa702-B14","year":"2017"},{"key":"2021061821290729600_keaa702-B15","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.3748\/wjg.v21.i11.3308","article-title":"Significant risk and associated factors of active tuberculosis infection in Korean patients with inflammatory bowel disease using anti-TNF agents","volume":"21","author":"Kim","year":"2015","journal-title":"World J Gastroenterol"},{"key":"2021061821290729600_keaa702-B16","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3346\/jkms.2015.30.2.173","article-title":"The risk of tuberculosis in Korean patients with inflammatory bowel disease receiving tumor necrosis factor-\u03b1 blockers","volume":"30","author":"Byun","year":"2015","journal-title":"J Korean Med Sci"},{"key":"2021061821290729600_keaa702-B17","doi-asserted-by":"crossref","first-page":"e292","DOI":"10.3346\/jkms.2018.33.e292","article-title":"Incidence of active tuberculosis within one year after tumor necrosis factor inhibitor treatment according to latent tuberculosis infection status in patients with inflammatory bowel disease","volume":"33","author":"Kang","year":"2018","journal-title":"J Korean Med Sci"},{"key":"2021061821290729600_keaa702-B18","first-page":"799","article-title":"Data resource profile: the National Health Information Database of the National Health Insurance Service in South Korea","volume":"46","author":"Cheol Seong","year":"2017","journal-title":"Int J Epidemiol"},{"key":"2021061821290729600_keaa702-B19","doi-asserted-by":"crossref","first-page":"R32","DOI":"10.1186\/ar3260","article-title":"Validation of rheumatoid arthritis diagnoses in health care utilization data","volume":"13","author":"Kim","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"2021061821290729600_keaa702-B20","year":"2013"},{"key":"2021061821290729600_keaa702-B21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6901a1","article-title":"Guidelines for the treatment of latent tuberculosis infection: recommendations from the National Tuberculosis Controllers Association and CDC, 2020","volume":"69","author":"Sterling","year":"2020","journal-title":"MMWR Recomm Rep"},{"key":"2021061821290729600_keaa702-B22","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1002\/acr.22063","article-title":"Prophylaxis for latent tuberculosis infection prior to anti-tumor necrosis factor therapy in low-risk elderly patients with rheumatoid arthritis: a decision analysis","volume":"65","author":"Hazlewood","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2021061821290729600_keaa702-B23","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1005136","article-title":"New regimens to prevent tuberculosis in adults with HIV infection","volume":"365","author":"Martinson","year":"2011","journal-title":"N Engl J Med"},{"key":"2021061821290729600_keaa702-B24","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1513\/AnnalsATS.201608-647OC","article-title":"Efficacy of treatment for latent tuberculosis in patients undergoing treatment with a tumor necrosis factor antagonist","volume":"14","author":"Lee","year":"2017","journal-title":"Ann Am Thorac Soc"},{"key":"2021061821290729600_keaa702-B25","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.jclinepi.2004.03.012","article-title":"New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality","volume":"57","author":"Sundararajan","year":"2004","journal-title":"J Clin Epidemiol"},{"key":"2021061821290729600_keaa702-B26","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/EDE.0000000000000595","article-title":"A propensity-score-based fine stratification approach for confounding adjustment when exposure is infrequent","volume":"28","author":"Desai","year":"2017","journal-title":"Epidemiology"},{"key":"2021061821290729600_keaa702-B27","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1080\/03610910902859574","article-title":"Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research","volume":"38","author":"Austin","year":"2009","journal-title":"Commun Stat Simul Comput"},{"key":"2021061821290729600_keaa702-B28","author":"Kleinbaum","year":"2012","edition":"3rd edn"},{"key":"2021061821290729600_keaa702-B29","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1136\/ard.2011.151043","article-title":"Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?","volume":"70","author":"Strangfeld","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2021061821290729600_keaa702-B30","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1002\/art.22808","article-title":"Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies","volume":"56","author":"Dixon","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2021061821290729600_keaa702-B31","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/art.22504","article-title":"Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists","volume":"56","author":"Curtis","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2021061821290729600_keaa702-B32","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1002\/art.34382","article-title":"Interferon-\u03b3 release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis","volume":"64","author":"Hsia","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2021061821290729600_keaa702-B33","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1001\/jama.2016.10357","article-title":"Primary care screening and treatment for latent tuberculosis infection in adults: evidence report and systematic review for the US Preventive Services Task Force","volume":"316","author":"Kahwati","year":"2016","journal-title":"JAMA"},{"key":"2021061821290729600_keaa702-B34","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1136\/thoraxjnl-2015-207811","article-title":"Effect of immunosuppressive therapy on interferon \u03b3 release assay for latent tuberculosis screening in patients with autoimmune diseases: a systematic review and meta-analysis","volume":"71","author":"Wong","year":"2016","journal-title":"Thorax"},{"key":"2021061821290729600_keaa702-B35","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jinf.2019.04.010","article-title":"Characterization of QuantiFERON-TB-Plus results in latent tuberculosis infected patients with or without immune-mediated inflammatory diseases","volume":"79","author":"Chiacchio","year":"2019","journal-title":"J Infect"},{"key":"2021061821290729600_keaa702-B36","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jiac.2017.09.012","article-title":"Lymphocyte subset analysis in QuantiFERON-TB Gold Plus and T-Spot.TB for latent tuberculosis infection in rheumatoid arthritis","volume":"24","author":"Igari","year":"2018","journal-title":"J Infect Chemother"},{"key":"2021061821290729600_keaa702-B37","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jctube.2018.04.006","article-title":"Korea Tuberculosis Epidemic Investigation Service. Tuberculosis prevention and care in Korea: evolution of policy and practice","volume":"11","author":"Go","year":"2018","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"2021061821290729600_keaa702-B38","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/j.1440-1843.2010.01751.x","article-title":"Treatment of latent tuberculosis infection: an update","volume":"15","author":"Lobue","year":"2010","journal-title":"Respirology"},{"key":"2021061821290729600_keaa702-B39","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S1473-3099(17)30703-X","article-title":"The global burden of tuberculosis: results from the Global Burden of Disease Study 2015","volume":"18","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2021061821290729600_keaa702-B40","first-page":"706","article-title":"Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers","volume":"34","author":"Seong","year":"2007","journal-title":"J Rheumatol"},{"key":"2021061821290729600_keaa702-B41","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1136\/annrheumdis-2019-216128","article-title":"Tuberculosis in biologic users for rheumatic diseases: results from the South African Biologics Registry (SABIO)","volume":"79","author":"Pettipher","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2021061821290729600_keaa702-B42","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1136\/annrheumdis-2015-207319","article-title":"Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis","volume":"75","author":"Winthrop","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2021061821290729600_keaa702-B43","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1056\/NEJMp1707387","article-title":"Tuberculosis elimination in the United States - the need for renewed action","volume":"377","author":"Bayer","year":"2017","journal-title":"N Engl J Med"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/6\/2755\/38694978\/keaa702.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/6\/2755\/38694978\/keaa702.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T21:30:15Z","timestamp":1624051815000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/60\/6\/2755\/5981745"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,14]]},"references-count":43,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,11,14]]},"published-print":{"date-parts":[[2021,6,18]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaa702","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,6,1]]},"published":{"date-parts":[[2020,11,14]]}}}